BioCentury
ARTICLE | Finance

Planting Fidelity's seeds

Why Fidelity decided to help create neurodegenerative play Denali

May 18, 2015 7:00 AM UTC

Fidelity Biosciences Research Initiative has helped create a neurodegenerative disease company that could serve as a repository for the discoveries stemming from seed investments in academia that FBRI has quietly been making for the past six years. The newco, Denali Therapeutics Inc., debuted last week with $217 million.

"While Fidelity Biosciences is disease-agnostic, we're mission driven and are focused on neurodegeneration," said Stacie Weninger, executive director of FBRI. "We find and fund everything from basic research in academia to early stage company research before a VC would get interested."...